Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1986 1
1993 1
1994 1
2000 1
2001 2
2004 2
2006 1
2007 1
2008 2
2009 2
2010 2
2011 4
2012 1
2013 2
2014 2
2015 2
2017 3
2018 5
2019 2
2020 7
2021 11
2022 13
2023 10
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

67 results

Results by year

Filters applied: . Clear all
Page 1
Global guidance for the recognition, diagnosis, and management of tumor-induced osteomalacia.
Jan de Beur SM, Minisola S, Xia WB, Abrahamsen B, Body JJ, Brandi ML, Clifton-Bligh R, Collins M, Florenzano P, Houillier P, Imanishi Y, Imel EA, Khan AA, Zillikens MC, Fukumoto S. Jan de Beur SM, et al. J Intern Med. 2023 Mar;293(3):309-328. doi: 10.1111/joim.13593. Epub 2022 Dec 13. J Intern Med. 2023. PMID: 36511653 Free PMC article. Review.
Tumor-induced osteomalacia (TIO) is a rare paraneoplastic syndrome caused by mesenchymal tumors that secrete fibroblast growth factor 23 (FGF23). ...TIO is characterized by hypophosphatemia, excess renal phosphate excretion, and low/inappropriately normal 1,2 …
Tumor-induced osteomalacia (TIO) is a rare paraneoplastic syndrome caused by mesenchymal tumors that secrete fibroblast …
Burosumab for the Treatment of Tumor-Induced Osteomalacia.
Jan de Beur SM, Miller PD, Weber TJ, Peacock M, Insogna K, Kumar R, Rauch F, Luca D, Cimms T, Roberts MS, San Martin J, Carpenter TO. Jan de Beur SM, et al. J Bone Miner Res. 2021 Apr;36(4):627-635. doi: 10.1002/jbmr.4233. Epub 2021 Jan 12. J Bone Miner Res. 2021. PMID: 33338281 Free PMC article. Clinical Trial.
Tumor-induced osteomalacia (TIO) is caused by phosphaturic mesenchymal tumors producing fibroblast growth factor 23 (FGF23) and is characterized by impaired phosphate metabolism, skeletal health, and quality of life. ...
Tumor-induced osteomalacia (TIO) is caused by phosphaturic mesenchymal tumors producing fibroblast growth factor 23 (FG …
FGF23-related hypophosphatemic rickets/osteomalacia: diagnosis and new treatment.
Fukumoto S. Fukumoto S. J Mol Endocrinol. 2021 Feb;66(2):R57-R65. doi: 10.1530/JME-20-0089. J Mol Endocrinol. 2021. PMID: 33295878 Review.
After the identification of FGF23, several kinds of hypophosphatemic rickets/osteomalacia such as X-linked hypophosphatemia (XLH) and tumor-induced osteomalacia (TIO) have been shown to be caused by excessive actions of FGF23. ...Chemiluminescent enzyme immun …
After the identification of FGF23, several kinds of hypophosphatemic rickets/osteomalacia such as X-linked hypophosphatemia (XLH) and tum …
Tumor-Induced Osteomalacia.
Florenzano P, Hartley IR, Jimenez M, Roszko K, Gafni RI, Collins MT. Florenzano P, et al. Calcif Tissue Int. 2021 Jan;108(1):128-142. doi: 10.1007/s00223-020-00691-6. Epub 2020 Jun 5. Calcif Tissue Int. 2021. PMID: 32504138 Review.
Tumor-induced osteomalacia (TIO) is a rare paraneoplastic syndrome caused by tumoral production of fibroblast growth factor 23 (FGF23). ...
Tumor-induced osteomalacia (TIO) is a rare paraneoplastic syndrome caused by tumoral production of fibroblast growth fa …
Rickets guidance: part II-management.
Haffner D, Leifheit-Nestler M, Grund A, Schnabel D. Haffner D, et al. Pediatr Nephrol. 2022 Oct;37(10):2289-2302. doi: 10.1007/s00467-022-05505-5. Epub 2022 Mar 29. Pediatr Nephrol. 2022. PMID: 35352187 Free PMC article.
Fibroblast-growth factor 23 (FGF23)-associated hypophosphatemic rickets was historically treated with frequent doses of oral phosphate salts in combination with active vitamin D, whereas tumor-induced osteomalacia (TIO) should primarily undergo tumor resectio …
Fibroblast-growth factor 23 (FGF23)-associated hypophosphatemic rickets was historically treated with frequent doses of oral phosphate salts …
FGF23 and Hypophosphatemic Rickets/Osteomalacia.
Takashi Y, Kawanami D, Fukumoto S. Takashi Y, et al. Curr Osteoporos Rep. 2021 Dec;19(6):669-675. doi: 10.1007/s11914-021-00709-4. Epub 2021 Nov 10. Curr Osteoporos Rep. 2021. PMID: 34755323 Review.
PURPOSE OF REVIEW: X-linked hypophosphatemia and tumor-induced osteomalacia are diseases characterized by hypophosphatemia with impaired proximal tubular phosphate reabsorption. Complete resection of responsible tumors is the first-line therapy for patients w …
PURPOSE OF REVIEW: X-linked hypophosphatemia and tumor-induced osteomalacia are diseases characterized by hypophosphate …
Phosphatonins: From Discovery to Therapeutics.
Kritmetapak K, Kumar R. Kritmetapak K, et al. Endocr Pract. 2023 Jan;29(1):69-79. doi: 10.1016/j.eprac.2022.09.007. Epub 2022 Oct 7. Endocr Pract. 2023. PMID: 36210014 Free article. Review.
Disorders of FGF23-related hypophosphatemia include X-linked hypophosphatemia (XLH), autosomal dominant hypophosphatemic rickets, autosomal recessive hypophosphatemic rickets, fibrous dysplasia/McCune-Albright syndrome, and tumor-induced osteomalacia (TIO). C …
Disorders of FGF23-related hypophosphatemia include X-linked hypophosphatemia (XLH), autosomal dominant hypophosphatemic rickets, autosomal …
Tumor-Induced Osteomalacia: A Systematic Clinical Review of 895 Cases.
Bosman A, Palermo A, Vanderhulst J, De Beur SMJ, Fukumoto S, Minisola S, Xia W, Body JJ, Zillikens MC. Bosman A, et al. Calcif Tissue Int. 2022 Oct;111(4):367-379. doi: 10.1007/s00223-022-01005-8. Epub 2022 Jul 20. Calcif Tissue Int. 2022. PMID: 35857061 Free PMC article. Review.
Tumor-induced osteomalacia (TIO) is a rare and largely underdiagnosed paraneoplastic condition. Previous reviews often reported incomplete data on clinical aspects, diagnosis or prognosis. The aim of this study was to present a systematic clinical …
Tumor-induced osteomalacia (TIO) is a rare and largely underdiagnosed paraneoplastic condition. Previous reviews often …
Tumor localization and biochemical response to cure in tumor-induced osteomalacia.
Chong WH, Andreopoulou P, Chen CC, Reynolds J, Guthrie L, Kelly M, Gafni RI, Bhattacharyya N, Boyce AM, El-Maouche D, Crespo DO, Sherry R, Chang R, Wodajo FM, Kletter GB, Dwyer A, Collins MT. Chong WH, et al. J Bone Miner Res. 2013 Jun;28(6):1386-98. doi: 10.1002/jbmr.1881. J Bone Miner Res. 2013. PMID: 23362135 Free PMC article.
Tumor-induced osteomalacia (TIO) is a rare disorder of phosphate wasting due to fibroblast growth factor-23 (FGF23)-secreting tumors that are often difficult to locate. ...
Tumor-induced osteomalacia (TIO) is a rare disorder of phosphate wasting due to fibroblast growth factor-23 (FGF23)-sec …
New Therapies for Hypophosphatemia-Related to FGF23 Excess.
Athonvarangkul D, Insogna KL. Athonvarangkul D, et al. Calcif Tissue Int. 2021 Jan;108(1):143-157. doi: 10.1007/s00223-020-00705-3. Epub 2020 Jun 5. Calcif Tissue Int. 2021. PMID: 32504139 Review.
The principle acquired form of FGF23-mediated hypophosphatemia is tumor-induced osteomalacia (TIO). This review summarizes current knowledge about the pathophysiology and clinical presentation of the most common FGF23-mediated conditions, with a focus …
The principle acquired form of FGF23-mediated hypophosphatemia is tumor-induced osteomalacia (TIO). This review summari …
67 results